

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/12		(11) International Publication Number: WO 98/05302
A1		(43) International Publication Date: 12 February 1998 (12.02.98)
<p>(21) International Application Number: PCT/GB97/01502</p> <p>(22) International Filing Date: 3 June 1997 (03.06.97)</p> <p>(30) Priority Data: 9616237.5 1 August 1996 (01.08.96) GB</p> <p>(71) Applicant (for all designated States except US): NORTON HEALTHCARE LIMITED [GB/GB]; Gemini House, Flex Meadow, Harlow, Essex CM29 5TJ (GB).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): MILLER, Fiona [GB/GB]; Norton Healthcare Limited, Gemini House, Flex Meadow, Harlow, Essex CM29 5TJ (GB).</p> <p>(74) Agent: PAWLYN, Anthony, Neil; Urquhart-Dykes & Lord, Tower House, Merriion Way, Leeds LS2 8PA (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report.</p>
<p>(54) Title: AEROSOL FORMULATIONS</p> <p>(57) Abstract</p> <p>The replacement of chlorofluorohydrocarbon propellants in medical aerosols is of the utmost importance to the pharmaceutical industry. A number of formulations have been investigated. The present invention provides a medical aerosol formulation comprising a particular medicament, a fluorocarbon propellant and 6 to 25 % w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant. Cannisters suitable for delivering such a pharmaceutical formulation are also provided.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TC	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KH	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

AEROSOL FORMULATIONS

This invention relates to pharmaceutical formulations for inhalation aerosols. The Montreal Protocol on ozone depleting gases has made the reformulation of existing pharmaceutical aerosols for inhalation treatment containing chlorofluorohydrocarbon propellants, a matter of urgency for the pharmaceutical industry.

A number of hydrofluorocarbons (HFCs) have been the subject to toxicological testing and two in particular P134a (1,1,1,2-tetrafluoroethane) and P227 (1,1,1,2,3,3,3-heptafluoropropane) have been identified as safe for use in pharmaceutical aerosols.

A number of patent applications have been submitted in this field, the first being EP 372777, which discloses the use of four component mixtures, comprising a medicament, a surfactant, P134a and a co-solvent of higher polarity than the P134a, in the form of a solution or a suspension.

As inhalation aerosols are meant for administration to the lung, it has long been accepted that such formulations should contain as few ingredients as possible, to avoid putting unnecessary materials into the lung.

Historically, despite EP 372777, solution aerosols contained only medicament, propellant or propellant mixtures and, if necessary, co-solvent, usually ethanol, eg US 2868691. The use of a surfactant was normally unnecessary for solution aerosols. However, historically medicinal suspension aerosols have contained a surfactant eg US 3014844, as it was considered that the use of a surfactant was necessary to prevent agglomeration of particles, to prevent adhesion to the sides of the canister, and to aid valve lubrication and prevent valve sticking.

However it was disclosed in EP 616525 that it is possible to prepare medicament suspensions in a hydrofluorocarbon without the need for a surfactant, if a polar co-solvent was added. The normal co-solvent ethanol, has well established

-2-

physiological actions and being a pure absorbable liquid eliminates any possibility of residues remaining in the lung. Irritation or possible toxicity from the surfactant, many of which are mixtures of similar compounds, are avoided.

EP 616525 specifically limits the polar co-solvent level to 0.01 to 5% w/w and in particular states (page 3, line 55) that the preferred level is about 0.1% w/w.

According to a first aspect of the present invention there is provided a medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.

According to a second aspect of the present invention there is provided a medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.

According to a third aspect of the present invention there is provided a canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

It has now been surprisingly found that higher levels of alcohol have beneficial results. Levels of 6% or more of ethanol produce satisfactory suspensions, which do not agglomerate on standing, and on reshaking produce finely dispersed medicament. It is believed that the higher levels of alcohol reduce the degree of deposition on the inside of the can. This is a very desirable feature. In addition, the use of these larger percentages of ethanol enables a much cheaper production process.

Medicinal aerosols can be filled either with one dose of liquid containing all of the ingredients mixed together or by

-3-

a two dose process where the first dose contains the medicament and all other ingredients, including co-solvents, surfactants, if any, ancillary compounds eg flavours, if any, and some times some of the propellant followed by a second dose of pure propellant. This two dose fill has major cost advantages in that the volume of mix for a fixed number of cans is significantly smaller enabling the use of smaller mixing vessels. In particular, with the use of the new HFC propellants, which have lower boiling points than the old CFC propellants, the use of a one dose fill may involve the use of cooled pressurised vessels to prevent evaporation of the propellant gas during mixing and filling. With the new formulations with added extra co-solvent a first mix of just medicament suspended in the co-solvent can be used, followed by a second dose of pure propellant. This means that the propellant can be dosed directly from a holding tank into the can without any need to mix and store with the other ingredients. For example a mix weight of 1g of medicament and co-solvent can be followed by 7.5g of propellant. In this way the volume to be mixed is reduced from 8.5g to 1g. All the examples in EP 616525 are of laboratory scale, where the handling problems are much easier, but all the formulations described are such that it would not be practicable to fill in two doses without mixing the propellant, as is the case with the present disclosure.

The description of the filling method given on page 5 lines 2-13 indicates that only a one dose filling method is envisaged.

In all cases of the present invention the medicament consists of a particle size suitable for inhalation into the lung and will thus be less than 100 microns, desirably less than 20 microns and preferably in the range of 1-10 microns, normally with a mean particle size 1-5 microns.

Medicaments which may be administered in aerosol formulations according to the invention include any drug useful in inhalation therapy which may be presented in a form which is substantially completely insoluble in the selected propellant.

-4-

Appropriate medicaments may thus be selected from, for example, analgesics, eg codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, eg diltiazem; antiallergics, eg cromoglycate, ketotifen or nedocromil; anti-infectives, eg cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, eg methapyrilene; anti-inflammatories, eg beclomethasone, flunisolide, budesonide, tipredane, triamcinolone acetonide or fluticasone; antitussives, eg noscapine; bronchodilators, eg ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, salbutamol, salmeterol, terbutaline, isoetharine, tolubuterol, orciprenaline; diuretics, eg amiloride; anticholinergics, eg ipratropium, atropine or oxitropium; hormones, eg cortisone, hydrocortisone or prednisolone; xanthines, eg aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, eg insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in the form of salts (eg as alkali metal or amine salts or as acid addition salts) or as esters (eg lower alkyl esters) or as solvates (eg hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

Preferred are those compounds which are also substantially insoluble in the co-solvent. Particularly preferred as medicament is salbutamol either as base or as a salt and especially salbutamol sulphate.

Co-solvents may be selected from polar alcohols and polyols, particularly C₁-C₆ aliphatic alcohols and polyols, such as propylene glycol, and preferably ethanol. Levels of co-solvent will be between 6% and 25% w/w of the total canister content, preferably between 10-15% w/w of canister content.

The propellant may be a hydrofluorocarbon, particularly P134a or P227. Other hydrofluorocarbons or hydrocarbons or aliphatic gases (eg Dimethylether) may be added to modify the

-5-

propellant characteristics as required.

The product is preferentially produced by weighing the active medicament and suspending it in the co-solvent. The appropriate amount of suspension is then dosed into the can, followed by a second dose of propellant or propellant mix. However, a one shot fill or any other equivalent method may be employed.

The normal medicinal product on the market has an actuator with spray orifice diameter of about 480 microns. However, with the larger percentages of ethanol envisaged in this invention, it is desirable that the co-solvent evaporates from the particles as rapidly as possible.

This is achieved by reducing the aperture to between 100-300 microns, which for the same dosage or drug, gives more rapid evaporation of the co-solvent. A particularly preferred embodiment of the invention is a combination of a level 10-15% co-solvent (normally ethanol) with a stem aperture of 150-250 microns.

The invention is further described by means of example but not in any limitative sense.

Example

Salbutamol Sulphate	0.03g
Ethanol	0.97g
Tetrafluoroethane (P134a)	7.5g

The salbutamol sulphate previously micronised to give over 90% of particles below 10 microns was weighed out and added to the ethanol. The suspension was mixed until it was smooth and uniform and then filled into the aerosol canister. The metering valve assembly was crimped (preferably vacuum crimped) on the canister and then the P134a was filled through the valve. The valve capacity is such as to deliver 100 micrograms of salbutamol, as salbutamol sulphate per actuation.

A particularly preferred use of such a canister is in a patient breath operated device rather than the normal hand

-6-

operated device. Such devices are available commercially such as those under the trade mark "Easi-Breathe".

-7-

Claims:

1. A medicinal aerosol formulation comprising a particulate medicament, a fluorocarbon propellant and 6% to 25% w/w of the total formulation of a polar co-solvent, such formulation being substantially free of surfactant.
2. A medicinal aerosol formulation, comprising one or more particulate medicaments, one or more fluorocarbon or hydrocarbon or aliphatic gas propellants and 6% to 25% w/w of a polar co-solvent.
3. A formulation as claimed in claim 1 or claim 2, wherein the medicament is an anti-allergic, a bronchodilator or an anti-inflammatory steroid.
4. A formulation as claimed in claim 3, where the medicament is ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropandamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, orciprenaline, salbutamol, salmeterol, sodium cromoglycate, fluticasone, beclomethasone or similar molecule and any physiologically acceptable salt, solvate or ester of such compound.
5. A formulation, as claimed in claims 1-3, where the medicament is a salt of salbutamol.
6. A formulation, as claimed in claims 1-3, where the medicament is a salt of formoterol (sometimes called eformoterol).
7. A formulation according to any of claims 1 to 5, wherein the propellant is 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n-propane.
8. A formulation according to any of claims 1 to 5,

-8-

where the co-solvent level is 10-15%.

9. A formulation according to any of claims 1-5, wherein the polar co-solvent is ethanol.

10. A canister suitable for delivering a pharmaceutical aerosol formulation, which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises particulate medicament, a propellant consisting all or part of fluorocarbon and 6% to 25% of a polar co-solvent, which is substantially free of surfactant.

11. A canister according to claim 9, fitted into an adaptor with an aperture of 100-300 microns.

12. A product according to claims 9 and 10 where the medicament is as per claim 4.

13. A product according to claims 9-11, where the medicament is a salt of salbutamol.

14. A product according to claims 9-11, where the medicament is a salt of formoterol.

15. A canister according to claims 9 and 10, which is actuated by a breath operated device.

16. A product according to claim 15, where the medicament is a salt of salbutamol.

17. A product according to claim 15, where the medicament is a salt of formoterol.

INTERNATIONAL SEARCH REPORT

Intern 11 Application No
PCT/GB 97/01502

A. CLASSIFICATION OF SUBJECT MATTER

A 61 K 9/12

According to International Patent Classification (IPC) or to both national classification and IPC ⁶

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

A 61 K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A, 93/11 745 (GLAXO GROUP LIMITED) 24 June 1993 (24.06.93), abstract; claims 1-15. --	1-5, 7-10
A	WO, A, 93/11 743 (GLAXO GROUP LIMITED) 24 June 1993 (24.06.93), abstract; claims 1-21. --	1-5, 7-10
A	WO, A, 94/03 153 (GLAXO GROUP LIMITED) 17 February 1994 (17.02.94), abstract; claims 1-12. --	1-5, 7-10
A	WO, A, 94/13 262 (JAGER et al.) 23 June 1994 (23.06.94), abstract; claims 1-38.	1-5, 7-9

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search
03 September 1997

Date of mailing of the international search report

26.09.97

Name and mailing address of the ISA
European Patent Office, P.O. 5818 Patentaan 2
NL - 2280 JE Rijswijk
Tel. (+31-70) 340-2040, Tlx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

SCHNASS e.h.

INTERNATIONAL SEARCH REPORT

-2-

International Application No
PCT/GB 97/01502

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	<p>especially claim 4. -----</p>	

ANHANG

zum Internationalen Recherchen-
bericht über die internationale
Patentansmeldung Nr.

ANNEX

to the International Search
Report to the International Patent
Application No.

ANNEXE

au rapport de recherche inter-
national relatif à la demande de brevet
international n°

PCT/GB 97/01502 SAE 16221B

In diesem Anhang sind die Mitglieder
der Patentfamilien der in obenge-
nannten internationalen Recherchenbericht
angeführten Patentdokumente angegeben.
Diese Angaben dienen nur zur Unter-
richtung und erfolgen ohne Gewähr.

This Annex lists the patent family
members relating to the patent documents
cited in the above-mentioned inter-
national search report. The Office is
in no way liable for these particulars
which are given merely for the purpose
of information.

La présente annexe indique les
membres de la famille de brevets
relatifs aux documents de brevets cités
dans le rapport de recherche inter-
national visé ci-dessus. Les renseigne-
ments fournis sont donnés à titre indica-
tif et n'engagent pas la responsabilité
de l'Office.

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche	Datum der Veröffentlichung Publication date Date de publication	Mitglieder der Patentfamilie Patent family members Membres de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
WO A1 9311743		AP A0 9200461 AP A1 402 AT E 128350 AU A1 308507 AU A1 308511 AU A1 308517 AU A1 308523 AU A1 308529 AU A1 308535 AU A1 308541 AU A1 308547 AU A1 308553 AU A1 308559 AU A1 308565 AU A1 308571 AU A1 308577 AU A1 308583 AU A1 308589 AU A1 308595 AU A1 308601 AU A1 308607 AU A1 308613 AU A1 308619 AU A1 308625 AU A1 308631 AU A1 308637 AU A1 308643 AU A1 308649 AU A1 308655 AU A1 308661 AU A1 308667 AU A1 308673 AU A1 308679 AU A1 308685 AU A1 308691 AU A1 308697 AU A1 308703 AU A1 308709 AU A1 308715 AU A1 308721 AU A1 308727 AU A1 308733 AU A1 308739 AU A1 308745 AU A1 308751 AU A1 308757 AU A1 308763 AU A1 308769 AU A1 308775 AU A1 308781 AU A1 308787 AU A1 308793 AU A1 308799 AU A1 308805 AU A1 308811 AU A1 308817 AU A1 308823 AU A1 308829 AU A1 308835 AU A1 308841 AU A1 308847 AU A1 308853 AU A1 308859 AU A1 308865 AU A1 308871 AU A1 308877 AU A1 308883 AU A1 308889 AU A1 308895 AU A1 308901 AU A1 308907 AU A1 308913 AU A1 308919 AU A1 308925 AU A1 308931 AU A1 308937 AU A1 308943 AU A1 308949 AU A1 308955 AU A1 308961 AU A1 308967 AU A1 308973 AU A1 308979 AU A1 308985 AU A1 308991 AU A1 308997 AU A1 309003 AU A1 309009 AU A1 309015 AU A1 309021 AU A1 309027 AU A1 309033 AU A1 309039 AU A1 309045 AU A1 309051 AU A1 309057 AU A1 309063 AU A1 309069 AU A1 309075 AU A1 309081 AU A1 309087 AU A1 309093 AU A1 309099 AU A1 309105 AU A1 309111 AU A1 309117 AU A1 309123 AU A1 309129 AU A1 309135 AU A1 309141 AU A1 309147 AU A1 309153 AU A1 309159 AU A1 309165 AU A1 309171 AU A1 309177 AU A1 309183 AU A1 309189 AU A1 309195 AU A1 309201 AU A1 309207 AU A1 309213 AU A1 309219 AU A1 309225 AU A1 309231 AU A1 309237 AU A1 309243 AU A1 309249 AU A1 309255 AU A1 309261 AU A1 309267 AU A1 309273 AU A1 309279 AU A1 309285 AU A1 309291 AU A1 309297 AU A1 309303 AU A1 309309 AU A1 309315 AU A1 309321 AU A1 309327 AU A1 309333 AU A1 309339 AU A1 309345 AU A1 309351 AU A1 309357 AU A1 309363 AU A1 309369 AU A1 309375 AU A1 309381 AU A1 309387 AU A1 309393 AU A1 309399 AU A1 309405 AU A1 309411 AU A1 309417 AU A1 309423 AU A1 309429 AU A1 309435 AU A1 309441 AU A1 309447 AU A1 309453 AU A1 309459 AU A1 309465 AU A1 309471 AU A1 309477 AU A1 309483 AU A1 309489 AU A1 309495 AU A1 309501 AU A1 309507 AU A1 309513 AU A1 309519 AU A1 309525 AU A1 309531 AU A1 309537 AU A1 309543 AU A1 309549 AU A1 309555 AU A1 309561 AU A1 309567 AU A1 309573 AU A1 309579 AU A1 309585 AU A1 309591 AU A1 309597 AU A1 309603 AU A1 309609 AU A1 309615 AU A1 309621 AU A1 309627 AU A1 309633 AU A1 309639 AU A1 309645 AU A1 309651 AU A1 309657 AU A1 309663 AU A1 309669 AU A1 309675 AU A1 309681 AU A1 309687 AU A1 309693 AU A1 309699 AU A1 309705 AU A1 309711 AU A1 309717 AU A1 309723 AU A1 309729 AU A1 309735 AU A1 309741 AU A1 309747 AU A1 309753 AU A1 309759 AU A1 309765 AU A1 309771 AU A1 309777 AU A1 309783 AU A1 309789 AU A1 309795 AU A1 309801 AU A1 309807 AU A1 309813 AU A1 309819 AU A1 309825 AU A1 309831 AU A1 309837 AU A1 309843 AU A1 309849 AU A1 309855 AU A1 309861 AU A1 309867 AU A1 309873 AU A1 309879 AU A1 309885 AU A1 309891 AU A1 309897 AU A1 309903 AU A1 309909 AU A1 309915 AU A1 309921 AU A1 309927 AU A1 309933 AU A1 309939 AU A1 309945 AU A1 309951 AU A1 309957 AU A1 309963 AU A1 309969 AU A1 309975 AU A1 309981 AU A1 309987 AU A1 309993 AU A1 309999 AU A1 310005 AU A1 310011 AU A1 310017 AU A1 310023 AU A1 310029 AU A1 310035 AU A1 310041 AU A1 310047 AU A1 310053 AU A1 310059 AU A1 310065 AU A1 310071 AU A1 310077 AU A1 310083 AU A1 310089 AU A1 310095 AU A1 310101 AU A1 310107 AU A1 310113 AU A1 310119 AU A1 310125 AU A1 310131 AU A1 310137 AU A1 310143 AU A1 310149 AU A1 310155 AU A1 310161 AU A1 310167 AU A1 310173 AU A1 310179 AU A1 310185 AU A1 310191 AU A1 310197 AU A1 310203 AU A1 310209 AU A1 310215 AU A1 310221 AU A1 310227 AU A1 310233 AU A1 310239 AU A1 310245 AU A1 310251 AU A1 310257 AU A1 310263 AU A1 310269 AU A1 310275 AU A1 310281 AU A1 310287 AU A1 310293 AU A1 310299 AU A1 310305 AU A1 310311 AU A1 310317 AU A1 310323 AU A1 310329 AU A1 310335 AU A1 310341 AU A1 310347 AU A1 310353 AU A1 310359 AU A1 310365 AU A1 310371 AU A1 310377 AU A1 310383 AU A1 310389 AU A1 310395 AU A1 310401 AU A1 310407 AU A1 310413 AU A1 310419 AU A1 310425 AU A1 310431 AU A1 310437 AU A1 310443 AU A1 310449 AU A1 310455 AU A1 310461 AU A1 310467 AU A1 310473 AU A1 310479 AU A1 310485 AU A1 310491 AU A1 310497 AU A1 310503 AU A1 310509 AU A1 310515 AU A1 310521 AU A1 310527 AU A1 310533 AU A1 310539 AU A1 310545 AU A1 310551 AU A1 310557 AU A1 310563 AU A1 310569 AU A1 310575 AU A1 310581 AU A1 310587 AU A1 310593 AU A1 310599 AU A1 310605 AU A1 310611 AU A1 310617 AU A1 310623 AU A1 310629 AU A1 310635 AU A1 310641 AU A1 310647 AU A1 310653 AU A1 310659 AU A1 310665 AU A1 310671 AU A1 310677 AU A1 310683 AU A1 310689 AU A1 310695 AU A1 310701 AU A1 310707 AU A1 310713 AU A1 310719 AU A1 310725 AU A1 310731 AU A1 310737 AU A1 310743 AU A1 310749 AU A1 310755 AU A1 310761 AU A1 310767 AU A1 310773 AU A1 310779 AU A1 310785 AU A1 310791 AU A1 310797 AU A1 310803 AU A1 310809 AU A1 310815 AU A1 310821 AU A1 310827 AU A1 310833 AU A1 310839 AU A1 310845 AU A1 310851 AU A1 310857 AU A1 310863 AU A1 310869 AU A1 310875 AU A1 310881 AU A1 310887 AU A1 310893 AU A1 310899 AU A1 310905 AU A1 310911 AU A1 310917 AU A1 310923 AU A1 310929 AU A1 310935 AU A1 310941 AU A1 310947 AU A1 310953 AU A1 310959 AU A1 310965 AU A1 310971 AU A1 310977 AU A1 310983 AU A1 310989 AU A1 310995 AU A1 311001 AU A1 311007 AU A1 311013 AU A1 311019 AU A1 311025 AU A1 311031 AU A1 311037 AU A1 311043 AU A1 311049 AU A1 311055 AU A1 311061 AU A1 311067 AU A1 311073 AU A1 311079 AU A1 311085 AU A1 311091 AU A1 311097 AU A1 311103 AU A1 311109 AU A1 311115 AU A1 311121 AU A1 311127 AU A1 311133 AU A1 311139 AU A1 311145 AU A1 311151 AU A1 311157 AU A1 311163 AU A1 311169 AU A1 311175 AU A1 311181 AU A1 311187 AU A1 311193 AU A1 311199 AU A1 311205 AU A1 311211 AU A1 311217 AU A1 311223 AU A1 311229 AU A1 311235 AU A1 311241 AU A1 311247 AU A1 311253 AU A1 311259 AU A1 311265 AU A1 311271 AU A1 311277 AU A1 311283 AU A1 311289 AU A1 311295 AU A1 311301 AU A1 311307 AU A1 311313 AU A1 311319 AU A1 311325 AU A1 311331 AU A1 311337 AU A1 311343 AU A1 311349 AU A1 311355 AU A1 311361 AU A1 311367 AU A1 311373 AU A1 311379 AU A1 311385 AU A1 311391 AU A1 311397 AU A1 311403 AU A1 311409 AU A1 311415 AU A1 311421 AU A1 311427 AU A1 311433 AU A1 311439 AU A1 311445 AU A1 311451 AU A1 311457 AU A1 311463 AU A1 311469 AU A1 311475 AU A1 311481 AU A1 311487 AU A1 311493 AU A1 311499 AU A1 311505 AU A1 311511 AU A1 311517 AU A1 311523 AU A1 311529 AU A1 311535 AU A1 311541 AU A1 311547 AU A1 311553 AU A1 311559 AU A1 311565 AU A1 311571 AU A1 311577 AU A1 311583 AU A1 311589 AU A1 311595 AU A1 311601 AU A1 311607 AU A1 311613 AU A1 311619 AU A1 311625 AU A1 311631 AU A1 311637 AU A1 311643 AU A1 311649 AU A1 311655 AU A1 311661 AU A1 311667 AU A1 311673 AU A1 311679 AU A1 311685 AU A1 311691 AU A1 311697 AU A1 311703 AU A1 311709 AU A1 311715 AU A1 311721 AU A1 311727 AU A1 311733 AU A1 311739 AU A1 311745 AU A1 311751 AU A1 311757 AU A1 311763 AU A1 311769 AU A1 311775 AU A1 311781 AU A1 311787 AU A1 311793 AU A1 311799 AU A1 311805 AU A1 311811 AU A1 311817 AU A1 311823 AU A1 311829 AU A1 311835 AU A1 311841 AU A1 311847 AU A1 311853 AU A1 311859 AU A1 311865 AU A1 311871 AU A1 311877 AU A1 311883 AU A1 311889 AU A1 311895 AU A1 311901 AU A1 311907 AU A1 311913 AU A1 311919 AU A1 311925 AU A1 311931 AU A1 311937 AU A1 311943 AU A1 311949 AU A1 311955 AU A1 311961 AU A1 311967 AU A1 311973 AU A1 311979 AU A1 311985 AU A1 311991 AU A1 311997 AU A1 312003 AU A1 312009 AU A1 312015 AU A1 312021 AU A1 312027 AU A1 312033 AU A1 312039 AU A1 312045 AU A1 312051 AU A1 312057 AU A1 312063 AU A1 312069 AU A1 312075 AU A1 312081 AU A1 312087 AU A1 312093 AU A1 312099 AU A1 312105 AU A1 312111 AU A1 312117 AU A1 312123 AU A1 312129 AU A1 312135 AU A1 312141 AU A1 312147 AU A1 312153 AU A1 312159 AU A1 312165 AU A1 312171 AU A1 312177 AU A1 312183 AU A1 312189 AU A1 312195 AU A1 312201 AU A1 312207 AU A1 312213 AU A1 312219 AU A1 312225 AU A1 312231 AU A1 312237 AU A1 312243 AU A1 312249 AU A1 312255 AU A1 312261 AU A1 312267 AU A1 312273 AU A1 312279 AU A1 312285 AU A1 312291 AU A1 312297 AU A1 312303 AU A1 312309 AU A1 312315 AU A1 312321 AU A1 312327 AU A1 312333 AU A1 312339 AU A1 312345 AU A1 312351 AU A1 312357 AU A1 312363 AU A1 312369 AU A1 312375 AU A1 312381 AU A1 312387 AU A1 312393 AU A1 312399 AU A1 312405 AU A1 312411 AU A1 312417 AU A1 312423 AU A1 312429 AU A1 312435 AU A1 312441 AU A1 312447 AU A1 312453 AU A1 312459 AU A1 312465 AU A1 312471 AU A1 312477 AU A1 312483 AU A1 312489 AU A1 312495 AU A1 312501 AU A1 312507 AU A1 312513 AU A1 312519 AU A1 312525 AU A1 312531 AU A1 312537 AU A1 312543 AU A1 312549 AU A1 312555 AU A1 312561 AU A1 312567 AU A1 312573 AU A1 312579 AU A1 312585 AU A1 312591 AU A1 312597 AU A1 312603 AU A1 312609 AU A1 312615 AU A1 312621 AU A1 312627 AU A1 312633 AU A1 312639 AU A1 312645 AU A1 312651 AU A1 312657 AU A1 312663 AU A1 312669 AU A1 312675 AU A1 312681 AU A1 312687 AU A1 312693 AU A1 312699 AU A1 312705 AU A1 312711 AU A1 312717 AU A1 312723 AU A1 312729 AU A1 312735 AU A1 312741 AU A1 312747 AU A1 312753 AU A1 312759 AU A1 312765 AU A1 312771 AU A1 312777 AU A1 312783 AU A1 312789 AU A1 312795 AU A1 312801 AU A1 312807 AU A1 312813 AU A1 312819 AU A1 312825 AU A1 312831 AU A1 312837 AU A1 312843 AU A1 312849 AU A1 312855 AU A1 312861 AU A1 312867 AU A1 312873 AU A1 312879 AU A1 312885 AU A1 312891 AU A1 312897 AU A1 312903 AU A1 312909 AU A1 312915 AU A1 312921 AU A1 312927 AU A1 312933 AU A1 312939 AU A1 312945 AU A1 312951 AU A1 312957 AU A1 312963 AU A1 312969 AU A1 312975 AU A1 312981 AU A1 312987 AU A1 312993 AU A1 312999 AU A1 313005 AU A1 313011 AU A1 313017 AU A1 313023 AU A1 313029 AU A1 313035 AU A1 313041 AU A1 313047 AU A1 313053 AU A1 313059 AU A1 313065 AU A1 313071 AU A1 313077 AU A1 313083 AU A1 313089 AU A1 313095 AU A1 313101 AU A1 313107 AU A1 313113 AU A1 313119 AU A1 313125 AU A1 313131 AU A1 313137 AU A1 313143 AU A1 313149 AU A1 313155 AU A1 313161 AU A1 313167 AU A1 313173 AU A1 313179 AU A1 313185 AU A1 313191 AU A1 313197 AU A1 313203 AU A1 313209 AU A1 313215 AU A1 313221 AU A1 313227 AU A1 313233 AU A1 313239 AU A1 313245 AU A1 313251 AU A1 313257 AU A1 313263 AU A1 313269 AU A1 313275 AU A1 313281 AU A1 313287 AU A1 313293 AU A1 313299 AU A1 313305 AU A1 313311 AU A1 313317 AU A1 313323 AU A1 313329 AU A1 313335 AU A1 313341 AU A1 313347 AU A1 313353 AU A1 313359 AU A1 313365 AU A1 313371 AU A1 313377 AU A1 313383 AU A1 313389 AU A1 313395 AU A1 313401 AU A1 313407 AU A1 313413 AU A1 313419 AU A1 313425 AU A1 313431 AU A1 313437 AU A1 313443 AU A1 313449 AU A1 313455 AU A1 313461 AU A1 313467 AU A1 313473 AU A1 313479 AU A1 313485 AU A1 313491 AU A1 313497 AU A1 313503 AU A1 313509 AU A1 313515 AU A1 313521 AU A1 313527 AU A1 313533 AU A1 313539 AU A1 313545 AU A1 313551 AU A1 313557 AU A1 313563 AU A1 313569 AU A1 313575 AU A1 313581 AU A1 313587 AU A1 313593 AU A1 313599 AU A1 313605 AU A1 313611 AU A1 313617 AU A1 313623 AU A1 313629 AU A1 313635 AU A1 313641 AU A1 313647 AU A1 313653 AU A1 313659 AU A1 313665 AU A1 313671 AU A1 313677 AU A1 313683 AU A1 313689 AU A1 313695 AU A1 313701 AU A1 313707 AU A1 313713 AU A1 313719 AU A1 313725 AU A1 313731 AU A1 313737 AU A1 313743 AU A1 313749 AU A1 313755 AU A1 313761 AU A1 313767 AU A1 313773 AU A1 313779 AU A1 313785 AU A1 313791 AU A1 313797 AU A1 313803 AU A1 313809 AU A1 313815 AU A1 313821 AU A1 313827 AU A1 313833 AU A1 313839 AU A1 313845 AU A1 313851 AU A1 313857 AU A1 313863 AU A1 313869 AU A1 313875 AU A1 313881 AU A1 313887 AU A1 313893 AU A1 313899 AU A1 313905 AU A1 313911 AU A1 313917 AU A1 313923 AU A1 313929 AU A1 313935 AU A1 313941 AU A1 313947 AU A1 313953 AU A1 313959 AU A1 313965 AU A1 313971 AU A	

WD	AI	9403153	17-02-94	AU	B2	670616	23	-07	-96
				AU	A1	70363796	09	-01	-97
				CN	A1	10888436	29	-06	-94
				EP	A1	6588101	21	-06	-97
				EP	A1	775484	28	-08	-97
				GB	A0	9216382	16	-09	-97
				JP	T2	7509475	19	-10	-95
				GB	A0	9216381	16	-09	-94
				ZA	A	9303477	23	-02	-94
WD	AI	9413262	23-06-94	AU	A1	57403794	04	-07	-94
				AU	A1	60486794	04	-07	-94
				AU	B2	6880227	24	-07	-97
				BG	A	99760	22	-02	-96
				CN	A	1093263	23	-11	-94
				CN	A3	9501490	23	-11	-94
				FI	A1	6674240	09	-06	-94
				FI	A	9522842	09	-06	-94
				GB	A0	9522842	09	-06	-94
				GB	A0	9522842	09	-06	-94
				GB	A1	9522842	09	-06	-94
				GB	B2	9522842	09	-06	-94
				HU	A0	9522842	09	-06	-94
				JP	A2	9522842	09	-06	-94
				LV	T2	9522842	09	-06	-94
				NO	A	9522842	09	-06	-94
				NO	A0	9522842	09	-06	-94
				NZ	A	9522842	09	-06	-94
				PL	A1	9522842	09	-06	-94
				SK	A3	9522842	09	-06	-94
				WO	A1	9522842	09	-06	-94
				ZA	A	9522842	09	-06	-94